0001209191-21-008101.txt : 20210205 0001209191-21-008101.hdr.sgml : 20210205 20210205164357 ACCESSION NUMBER: 0001209191-21-008101 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210203 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 21596614 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-03 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2021-02-03 4 A 0 8438 0.00 A 43617 D Common Stock 2021-02-03 4 A 0 12388 0.00 A 56005 D Common Stock 2021-02-03 4 A 0 13952 0.00 A 69957 D Common Stock 2021-02-03 4 M 0 1554 86.52 A 71511 D Common Stock 2021-02-03 4 S 0 148 211.22 D 71363 D Common Stock 2021-02-03 4 S 0 488 212.77 D 70875 D Common Stock 2021-02-03 4 S 0 497 213.90 D 70378 D Common Stock 2021-02-03 4 S 0 242 214.98 D 70136 D Common Stock 2021-02-03 4 S 0 90 215.80 D 70046 D Common Stock 2021-02-03 4 S 0 89 216.83 D 69957 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 86.52 2021-02-03 4 M 0 1554 0.00 D 2027-02-02 Common Stock 1554 0 D Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Restricted stock unit award that vests in installments beginning on 02/17/2022. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $211.22 (range $211.06 to $211.27). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $212.77 (range $212.29 to $213.20). Open market sales reported on this line occurred at a weighted average price of $213.90 (range $213.49 to $214.17). Open market sales reported on this line occurred at a weighted average price of $214.98 (range $214.72 to $215.36). Fully vested. /s/ Sabrina Yohai, Attorney-in-Fact 2021-02-05